Read by QxMD icon Read

Ophthalmology angiogenesis

Kornelija Ruskyte, Rasa Liutkevicienė, Alvita Vilkeviciute, Paulina Vaitkiene, Indre Valiulytė, Brigita Glebauskiene, Loresa Kriauciuniene, Dalia Zaliuniene
Pituitary adenoma (PA) is one of the most common abnormalities in the sellar region. Despite the fact that PA is a benign monoclonal neoplasm, it can cause serious complications, including ophthalmological, neurological and endocrinological abnormalities. Currently, the causes that increase the progression of tumors are unknown. Epigenetic silencing of the matrix metalloproteinase-14 (MMP-14) and transforming growth factor beta-1 (TGFβ-1) genes may be associated with the development of PA, since these genes are important in the processes of tumor metastasis and angiogenesis...
October 2016: Oncology Letters
Beatriz Fernández-Vega, Álvaro Fernández-Vega, Carlos Mario Rangel, Javier Nicieza, Eva Villota-Deleu, José A Vega, Ronald M Sanchez-Avila
AIMS: To report a case of wet age-related macular degeneration (wet-AMD) refractory to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in a patient who showed visual and anatomical improvement and stabilization after starting a subcutaneous treatment course with adalimumab, an anti-tumor necrosis factor-alpha (TNF-α) drug, for concomitant Crohn's disease. METHODS: Observational case report of a female patient. Ophthalmological evaluation was performed by slit lamp and ophthalmoscopy (posterior pole and anterior segment)...
January 2016: Case Reports in Ophthalmology
M Cernak, L Nogova
UNLABELLED: Antiangiogenic drugs are approved for many cancer types for longer than a decade. Furthermore, several antiangiogenic agents are approved for local application in ophthalmology for treatment of macular degeneration, venous retinal occlusion and diabetic retinopathy. Knowing that antiangiogenic agents are active in ocular system, we reviewed the current literature, whether antiangiogenic drugs may cause ocular side effects in cancer patients by systemic application. Furthermore, we searched in published papers, if systemic application of antiangiogenic agents in cancer patients may simultaneously treat their ocular disorders, if they have such...
2016: Neoplasma
Napoleone Ferrara, Anthony P Adamis
The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both normal and pathological angiogenesis, has revealed innovative therapeutic approaches in oncology and ophthalmology. The first VEGFA inhibitor, bevacizumab, was approved by the US Food and Drug Administration in 2004 for the first-line treatment of metastatic colorectal cancer, and the first VEGFA inhibitors in ophthalmology, pegaptanib and ranibizumab, were approved in 2004 and 2006, respectively. To mark this tenth anniversary of anti-VEGFA therapy, we discuss the discovery of VEGFA, the successes and challenges in the development of VEGFA inhibitors and the impact of these agents on the treatment of cancers and ophthalmic diseases...
June 2016: Nature Reviews. Drug Discovery
Hendrik Gille, Martin Hülsmeyer, Stefan Trentmann, Gabriele Matschiner, Hans Jürgen Christian, Todd Meyer, Ali Amirkhosravi, Laurent P Audoly, Andreas M Hohlbaum, Arne Skerra
Human tear lipocalin (Tlc) was utilized as a protein scaffold to engineer an Anticalin that specifically binds and functionally blocks vascular endothelial growth factor A (VEGF-A), a pivotal inducer of physiological angiogenesis that also plays a crucial role in several neovascular diseases. Starting from a naive combinatorial library where residues that form the natural ligand-binding site of Tlc were randomized, followed by affinity maturation, the final Anticalin PRS-050 was selected to bind all major splice forms of VEGF-A with picomolar affinity...
January 2016: Angiogenesis
Cynthia Cheng, Chadd W Lee, Constantine Daskalakis
Capillaroscopy is a non-invasive, efficient, relatively inexpensive and easy to learn methodology for directly visualizing the microcirculation. The capillaroscopy technique can provide insight into a patient's microvascular health, leading to a variety of potentially valuable dermatologic, ophthalmologic, rheumatologic and cardiovascular clinical applications. In addition, tumor growth may be dependent on angiogenesis, which can be quantitated by measuring microvessel density within the tumor. However, there is currently little to no standardization of techniques, and only one publication to date reports the reliability of a currently available, complex computer based algorithms for quantitating capillaroscopy data...
October 27, 2015: Journal of Visualized Experiments: JoVE
Filippa Fleetwood, Rezan Güler, Emma Gordon, Stefan Ståhl, Lena Claesson-Welsh, John Löfblom
Angiogenesis denotes the formation of new blood vessels from pre-existing vasculature. Progression of diseases such as cancer and several ophthalmological disorders may be promoted by excess angiogenesis. Novel therapeutics to inhibit angiogenesis and diagnostic tools for monitoring angiogenesis during therapy, hold great potential for improving treatment of such diseases. We have previously generated so-called biparatopic Affibody constructs with high affinity for the vascular endothelial growth factor receptor-2 (VEGFR2), which recognize two non-overlapping epitopes in the ligand-binding site on the receptor...
April 2016: Cellular and Molecular Life Sciences: CMLS
Š Tuček, A Jurečková, J Tomášek, D Adámková Krákorová, J Halámková, L Pochop
Inhibition of angiogenesis is a valid approach in today's medicine. Besides oncology, it is used in ophthalmology, as well. In oncology, angiogenesis inhibition has become a routine and accessible method. A combination of angiogenesis inhibition and other therapies, including anticoagulation and antiaggregation is common in many cases. Bevacizumab is the most used antiangiogenic agent and has been in use for the longest period of time. A concomitant administration of angiogenesis inhibitors and anticoagulation may be feared by oncologists...
2015: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
A G Shchuko, I V Zlobin, T N Yur'eva, A A Ostanin, E R Chernykh
AIM: To study the concentrations of intraocular cytokines in patients with retinal vein occlusion (RVO) before and after intravitreal ranibizumab injection and to compare the results with clinical activity of the disease and treatment efficacy. MATERIAL AND METHODS: A comprehensive ophthalmological examination of 44 patients with RVO and macular edema was performed. Intraocular fluid was first collected before the intravitreal injection. Cytokines concentrations were measured using Bio-Plex Pro Human Cytokine 27-plex Panel (Bio-Rad Laboratories, USA) for flow cytometry...
March 2015: Vestnik Oftalmologii
Vincenzo De Sanctis, Carlo Incorvaia, Ashraf T Soliman, Giancarlo Candini, Alessia Pepe, Christos Kattamis, Nada A Soliman, Heba Elsedfy, Mohamed El Kholy
RATIONALE: Both insulin and IGF-1 have been implicated in the control of retinal endothelial cell growth, neovascularization and diabetic retinopathy. Recent findings have established an essential role for IGF-1 in angiogenesis and demonstrated a new target for control of retinopathy that explains why diabetic retinopathy initially increases with the onset of insulin treatment. OBJECTIVE: This cross-sectional study was designed to give insights into relationship between Insulin-Growth-Factor 1 (IGF-1) levels and diabetic retinopathy (DR) in a sample of thalassemia major (TM) patients with insulin dependent diabetes mellitus (IDDM)...
2015: Mediterranean Journal of Hematology and Infectious Diseases
Marcella Nebbioso, Giuseppe Buomprisco, Antonia Pascarella, Nicola Pescosolido
Many studies have shown that the presence of 1,25-dihydroxyvitamin D3 in the eye is able to modulate inflammatory responses. In fact, it has been demonstrated that topical administration of vitamin D3 inhibits Langerhans cells migration from the central cornea, corneal neovascularization, and production of cytokines (i.e. interleukin-1-6-8) in experimental animals. Moreover, both in vitro and in vivo studies have demonstrated that vitamin D is a potent inhibitor of retinal neovascularization. It has been shown that calcitriol, the biologically active form of vitamin D, inhibits angiogenesis both in cultured endothelial cells and in retinas from guinea pigs with retinoblastoma or oxygen-induced ischemic retinopathy...
June 9, 2015: Critical Reviews in Food Science and Nutrition
Nivriti Gahlaut, Sandra Suarez, Md Imam Uddin, Andrew Y Gordon, Stephanie M Evans, Ashwath Jayagopal
Retinal vascular diseases, including diabetic retinopathy, neovascular age related macular degeneration, and retinal vein occlusion, are leading causes of blindness in the Western world. These diseases share several common disease mechanisms, including vascular endothelial growth factor (VEGF) signaling, hypoxia, and inflammation, which provide opportunities for common therapeutic strategies. Treatment of these diseases using laser therapy, anti-VEGF injections, and/or steroids has significantly improved clinical outcomes...
September 2015: European Journal of Pharmaceutics and Biopharmaceutics
Shokoufeh Bonakdaran, Nasser Shoeibi
AIM: To determine a relation between vitamin D level, which is an inhibitor of angiogenesis, and diabetic retinopathy and its risk factors. METHODS: In a clinic-based cross sectional study two hundred and thirty-five type 2 diabetic patients older than 20y were selected. Patients were classified according to ophthalmologic examination as following: no diabetic retinopathy (NDR) (n=153), non-proliferative diabetic retinopathy (NPDR) (n=64) and proliferative diabetic retinopathy (PDR) (n=18)...
2015: International Journal of Ophthalmology
Yoshio Hirano, Tsutomu Yasukawa, Akiyo Tsukada, Sachiko Yokoyama, Yuya Ito, Yoko Nakazawa
An 81-year-old woman presented with blurred vision in the left eye. Best corrected visual acuity was 20/100. Ophthalmologic examination in the left eye revealed tilted disc syndrome with exudative change at the margin of inferior staphyloma. The exudative change persisted despite monthly intravitreal ranibizumab injections for 5 months. Subsequently, two intravitreal aflibercept injections 1 month apart were substituted for the ranibizumab injections, resulting in successful resolution of the exudative change...
March 2015: Ophthalmic Surgery, Lasers & Imaging Retina
Deborah Cohen
No abstract text is available yet for this article.
2015: BMJ: British Medical Journal
Maurizio Battaglia Parodi, Giuseppe Querques
PURPOSE: To describe a case of extensive macular atrophy and pseudodrusen complicated by bilateral choroidal neovascularization (CNV). METHODS: A 53-year-old woman showed extensive macular atrophy at the posterior pole associated with disciform scar in the right eye and fibrotic juxtafoveal CNV in the left eye. RESULTS: The patient underwent a complete ophthalmological examination including fundus autofluorescence, fluorescein angiography, and spectral-domain optical coherence tomography, showing a disciform scar at the posterior pole of the right eye and an extensive macular atrophy associated with a fibrotic juxtafoveal CNV...
April 2015: Optometry and Vision Science: Official Publication of the American Academy of Optometry
Helio F Shiroma, Michel E Farah, Walter Y Takahashi, Andre M V Gomes, Mauro Goldbaum, Eduardo Buchele Rodrigues
PURPOSE: To evaluate and describe the precautions involved in the technique of intravitreal injection of antiangiogenic drugs adopted by the ophthalmologists who are members of the Brazilian Society of Retina and Vitreous (SBRV). METHODS: A questionnaire containing 22 questions related to precautions taken before, during, and after intravitreal injection was sent electronically to 920 members of SBRV between November 15, 2013 and April 31, 2014. RESULTS: 352 responses (38%) were obtained...
January 2015: Arquivos Brasileiros de Oftalmologia
Sara Brandi Bloch, Michael Larsen
No abstract text is available yet for this article.
March 2015: Acta Ophthalmologica
Georges Azar, Martine Mauget-Faÿsse, Jasmine Nyouma, Salomon Yves Cohen, Florence Coscas, Catherine Français-Maury, Eric Souied, Gisèle Soubrane
PURPOSE: To report the occurrence and study the characteristics of macular hematoma after ranibizumab (anti-VEGF) intravitreal injection for subfoveal choroidal neovascularization in age-related macular degeneration (AMD). METHODS: The charts of 6000 patients treated with ranibizumab (0.5 mg) for exudative AMD were reviewed. Inclusion criteria were a minimum follow-up of 1 year after the first injection and the occurrence of a large macular hematoma involving the fovea in patients with macular lesions considered stabilized or still active...
March 2015: European Journal of Ophthalmology
Werner Eisenbarth, Nikolaus Feucht, Christian Enders, Mathias Maier, Chris P Lohmann, Manfred MacKeben
OBJECTIVE: The standard measure for the assessment of functional vision in the central retina is best corrected visual acuity (VA). Our aim was to investigate whether it is an advantage to include tests for functional changes in the near retinal periphery to monitor treatment effects in patients receiving multiple injections of anti-vascular endothelial growth factor (anti-VEGF) agents for advanced exudative age-related macular degeneration (AMD). DESIGN: Prospective pilot study...
February 2015: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"